<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392067</url>
  </required_header>
  <id_info>
    <org_study_id>LEO19123-C21</org_study_id>
    <nct_id>NCT00392067</nct_id>
  </id_info>
  <brief_title>LEO19123 Cream in the Treatment of Atopic Dermatitis</brief_title>
  <official_title>LEO19123 Cream in the Treatment of Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of two different dose combinations of LEO19123&#xD;
      (calcipotriol and LEO80122) with LEO19123 cream vehicle for 3 weeks in the treatment of&#xD;
      patients with atopic dermatitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proof of concept</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Atopic Dermatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol and LEO80122 (LEO19123 cream)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of atopic dermatitis according to Hanifin and Rajka&#xD;
&#xD;
          -  The score of erythema, induration/papulation, excoriation and lichenification, four of&#xD;
             the five clinical signs in the Total Severity Score, should at least correspond to&#xD;
             moderate involvement, i.e. severity greater than or equal to 2, at Visit 1&#xD;
&#xD;
          -  Treatment area amenable to topical treatment&#xD;
&#xD;
          -  Attending a hospital outpatient clinic or the private practice of a dermatologist&#xD;
&#xD;
          -  Following verbal and written information about the trial, the patient must provide&#xD;
             signed and dated informed consent before any study related activity is carried out,&#xD;
             including activities relating to washout period&#xD;
&#xD;
          -  Males between 18-50 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine,&#xD;
             azathioprine) or corticosteroids within 4 weeks prior to randomisation. (Inhaled or&#xD;
             intranasal steroids for asthma or rhinitis may be used)&#xD;
&#xD;
          -  PUVA or UVB therapy within 4 weeks prior to randomisation&#xD;
&#xD;
          -  Topical treatment with immunomodulators (pimecrolimus, tacrolimus) or corticosteroids&#xD;
             from WHO groups III or IV within 2 weeks prior to randomisation&#xD;
&#xD;
          -  Other topical therapy on the treatment area (except for the use of emollient on the&#xD;
             entire body and use of hydrocortisone cream 1% on AD lesions on head and neck) within&#xD;
             1 week prior to randomisation&#xD;
&#xD;
          -  Use of any other kind of treatment (drug, non-drug) for AD during the study except for&#xD;
             the use of: - Investigational product on trunk and limbs lesions only during the&#xD;
             treatment phase - Hydrocortisone cream 1% on head and neck lesions - Emollient on the&#xD;
             entire body&#xD;
&#xD;
          -  Use of anti-histamines during the study&#xD;
&#xD;
          -  Current diagnosis of exfoliative erythrodermia&#xD;
&#xD;
          -  Clinical infection (impetiginised atopic dermatitis) on the treatment area&#xD;
&#xD;
          -  Planned exposure to amount of sun or ultraviolet light during the study that may&#xD;
             affect atopic dermatitis&#xD;
&#xD;
          -  Known or suspected hypersensitivity to component(s) of the investigational product&#xD;
&#xD;
          -  Known or suspected severe renal insufficiency or severe hepatic disorders&#xD;
&#xD;
          -  Patients with history/signs/symptoms suggestive of an abnormality of calcium&#xD;
             homeostasis associated with clinically significant hypercalcaemia&#xD;
&#xD;
          -  Patients with history of cancer including skin cancer&#xD;
&#xD;
          -  Patients with history of an immunocompromised disease (e.g. lymphoma, HIV,&#xD;
             Wiskott-Aldrich Syndrome)&#xD;
&#xD;
          -  Current participation in any other interventional clinical trial&#xD;
&#xD;
          -  Patients who have received treatment with any non-marketed drug substance (i.e. an&#xD;
             agent which has not yet been made available for clinical use following registration)&#xD;
             within 4 weeks prior to randomisation&#xD;
&#xD;
          -  Previously randomised in this study&#xD;
&#xD;
          -  Patients known or suspected of not being able to comply with a trial protocol (e.g.&#xD;
             alcoholism, drug dependency, or psychotic state)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristian Thestrup-Pedersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hudklinikken</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Dermatologique Maizerets</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudklinikken</name>
      <address>
        <city>Nyk√∏bing F</city>
        <zip>4800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>October 24, 2006</study_first_submitted>
  <study_first_submitted_qc>October 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2006</study_first_posted>
  <last_update_submitted>April 29, 2008</last_update_submitted>
  <last_update_submitted_qc>April 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

